MX375256B - Metodo para tratar canceres de mama positivos a receptor de androgeno (ar) con modulador de receptor de androgeno selectivo (sarms). - Google Patents

Metodo para tratar canceres de mama positivos a receptor de androgeno (ar) con modulador de receptor de androgeno selectivo (sarms).

Info

Publication number
MX375256B
MX375256B MX2015000572A MX2015000572A MX375256B MX 375256 B MX375256 B MX 375256B MX 2015000572 A MX2015000572 A MX 2015000572A MX 2015000572 A MX2015000572 A MX 2015000572A MX 375256 B MX375256 B MX 375256B
Authority
MX
Mexico
Prior art keywords
breast cancer
treating
subject
subject suffering
positive
Prior art date
Application number
MX2015000572A
Other languages
English (en)
Other versions
MX2015000572A (es
Inventor
James T Dalton
Mitchell S Steiner
Ramesh Narayanan
Sunjoo Ahn
Original Assignee
Gtx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gtx Inc filed Critical Gtx Inc
Publication of MX2015000572A publication Critical patent/MX2015000572A/es
Publication of MX375256B publication Critical patent/MX375256B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/02—Carbamic acids; Salts of carbamic acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Electrotherapy Devices (AREA)

Abstract

Esta invención se refiere al tratamiento del cáncer de mama positivo a receptor de andrógeno en un sujeto, por ejemplo una mujer. Por consiguiente, esta invención proporciona métodos para: a) tratar a un sujeto que padece cáncer de mama; b) tratar a un sujeto que padece cáncer de mama metastásico; c) tratar a un sujeto que padece cáncer de mama refractario; d) tratar a un sujeto que padece cáncer de mama positivo a AR; e) tratar a un sujeto que padece cáncer de mama refractario positivo a AR; f) tratar a un sujeto que padece cáncer de mama metastásico positivo para AR; g) tratar a un sujeto que padece cáncer de mama positivo a AR y positivo a ER; h) tratar a un sujeto que padece cáncer de mama triple negativo; i) tratar a un sujeto que padece cáncer mama avanzado; j) tratar a un sujeto que padece cáncer de mama que ha fallado a tratamientos con SERM (tamixifeno, toromifeno), un inhibidor de aromatasa, trastuzumab (Herceptin, ado-trastuzumab emtansina), pertuzumab (Perjeta), lapatinib, exemestano (Aromasin), bevacizumab (Avastin) y/o fulvestrant; k) tratar, prevenir, suprimir o inhibir metástasis en un sujeto que padece cáncer de mama; 1) prolongar la supervivencia de un sujeto con cáncer de mama; y/o prolongar la supervivencia libre de progresión de un sujeto con cáncer de mama; que comprende administrar al sujeto una cantidad terapéuticamente efectiva de un compuesto modulador de receptor de andrógeno selectivo (SARM), que comprende administrar al sujeto una cantidad terapéuticamente efectiva de un compuesto SARM de esta invención.
MX2015000572A 2012-07-13 2013-03-07 Metodo para tratar canceres de mama positivos a receptor de androgeno (ar) con modulador de receptor de androgeno selectivo (sarms). MX375256B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261671366P 2012-07-13 2012-07-13
US201261726274P 2012-11-14 2012-11-14
PCT/US2013/029667 WO2014011220A2 (en) 2012-07-13 2013-03-07 A method of treating androgen receptor (ar)-positive breast cancers with selective androgen receptor modulator (sarms)

Publications (2)

Publication Number Publication Date
MX2015000572A MX2015000572A (es) 2015-09-23
MX375256B true MX375256B (es) 2025-03-06

Family

ID=49914508

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015000572A MX375256B (es) 2012-07-13 2013-03-07 Metodo para tratar canceres de mama positivos a receptor de androgeno (ar) con modulador de receptor de androgeno selectivo (sarms).
MX2020009725A MX2020009725A (es) 2012-07-13 2015-01-13 Metodo para tratar canceres de mama positivos a receptor de androgeno (ar) con modulador de receptor de androgeno selectivo (sarms).

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020009725A MX2020009725A (es) 2012-07-13 2015-01-13 Metodo para tratar canceres de mama positivos a receptor de androgeno (ar) con modulador de receptor de androgeno selectivo (sarms).

Country Status (20)

Country Link
US (1) US9604916B2 (es)
EP (2) EP2872482B1 (es)
JP (3) JP6226978B2 (es)
KR (2) KR102238970B1 (es)
CN (3) CN110840870A (es)
AU (3) AU2013203600C1 (es)
CA (1) CA2879049C (es)
CY (1) CY1123542T1 (es)
DK (1) DK2872482T3 (es)
ES (1) ES2818915T3 (es)
HR (1) HRP20201463T1 (es)
HU (1) HUE052574T2 (es)
IL (1) IL236681B (es)
IN (1) IN2015DN01046A (es)
LT (1) LT2872482T (es)
MX (2) MX375256B (es)
PL (1) PL2872482T3 (es)
PT (1) PT2872482T (es)
RU (2) RU2717835C2 (es)
WO (1) WO2014011220A2 (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9884038B2 (en) 2004-06-07 2018-02-06 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
US20090215731A1 (en) 2005-10-19 2009-08-27 Chavah Pty Ltd. Reduction of Side Effects From Aromatase Inhibitors Used for Treating Breast Cancer
US9844528B2 (en) 2006-08-24 2017-12-19 University Of Tennessee Research Foundation SARMs and method of use thereof
US10010521B2 (en) 2006-08-24 2018-07-03 University Of Tennessee Research Foundation SARMs and method of use thereof
US9730908B2 (en) 2006-08-24 2017-08-15 University Of Tennessee Research Foundation SARMs and method of use thereof
US7968603B2 (en) 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
MX375256B (es) 2012-07-13 2025-03-06 Gtx Inc Metodo para tratar canceres de mama positivos a receptor de androgeno (ar) con modulador de receptor de androgeno selectivo (sarms).
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
JP5958483B2 (ja) * 2013-07-31 2016-08-02 株式会社村田製作所 電力増幅モジュール
US20160106702A1 (en) * 2014-10-16 2016-04-21 Gtx, Inc. METHODS OF TREATING UROLOGICAL DISORDERS USING SARMs
CN107405353B (zh) 2014-10-22 2021-07-30 哈瓦赫治疗有限公司 降低乳房摄影乳腺密度和/或乳腺癌风险的方法
WO2016141458A1 (en) 2015-03-12 2016-09-15 British Columbia Cancer Agency Branch Bisphenol ether derivatives and methods for using the same
AR104257A1 (es) * 2015-04-16 2017-07-05 Novartis Ag Tableta de ribociclib
US10314797B2 (en) * 2016-06-10 2019-06-11 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10865184B2 (en) 2015-04-21 2020-12-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10093613B2 (en) 2015-04-21 2018-10-09 Gtx, Inc. Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10441570B2 (en) 2015-04-21 2019-10-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) Ligands and methods of use thereof
WO2016172358A1 (en) * 2015-04-21 2016-10-27 Gtx, Inc. Selective androgen receptor degrader (sard) ligands and methods of use thereof
US10017471B2 (en) 2015-04-21 2018-07-10 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
EP3285757B1 (en) 2015-04-21 2021-09-22 Oncternal Therapeutics, Inc. Selective androgen receptor degrader (sard) ligands and methods of use thereof
US9834507B2 (en) 2015-04-21 2017-12-05 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10806720B2 (en) 2015-04-21 2020-10-20 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10035763B2 (en) 2015-04-21 2018-07-31 Gtx, Inc. Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10654809B2 (en) 2016-06-10 2020-05-19 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
EP3364978A4 (en) 2015-10-22 2019-06-05 Havah Therapeutics Pty Ltd METHOD FOR REDUCING MAMMOGRAPHIC BREAST DENSITY AND / OR BREAST CANCER RISK
JP6926189B2 (ja) 2016-04-01 2021-08-25 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー エストロゲン受容体調節薬
US20170298033A1 (en) 2016-04-15 2017-10-19 The University Of British Columbia Bisphenol derivatives and their use as androgen receptor activity modulators
US10806719B2 (en) 2016-06-10 2020-10-20 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US11230523B2 (en) 2016-06-10 2022-01-25 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
MX392531B (es) * 2017-06-29 2025-03-24 G1 Therapeutics Inc Formas morficas de g1t38 y metodos de preparacion de las mismas.
AU2019271129B2 (en) 2018-05-14 2023-03-09 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
US11485713B2 (en) 2018-05-25 2022-11-01 Essa Pharma, Inc. Androgen receptor modulators and methods for their use
US12202815B2 (en) 2018-09-05 2025-01-21 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
CN109761778A (zh) * 2018-12-10 2019-05-17 石家庄市度智医药科技有限公司 一种合成光学活性α-羟基丙酰胺衍生物的方法
AU2020248105A1 (en) * 2019-03-28 2021-11-11 Essa Pharma, Inc. Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
WO2020198712A1 (en) 2019-03-28 2020-10-01 Essa Pharma, Inc. Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
WO2020205608A1 (en) * 2019-03-29 2020-10-08 Emory University Uses of androgen receptor antagonists and jnk pathway inhibitors, and pharmaceutical compositions related thereto
WO2020232119A1 (en) * 2019-05-14 2020-11-19 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
WO2020243373A1 (en) * 2019-05-29 2020-12-03 University Of Tennessee Research Foundation Selective androgen receptor degrader (sard) ligands and methods of use thereof
CA3142193A1 (en) 2019-06-03 2020-12-10 Havah Therapeutics Pty Ltd Pharmaceutical formulations and systems for delivery of an androgenic agent and an aromatase inhibitor and methods for use
EP3993787A4 (en) 2019-08-06 2023-07-12 Recurium IP Holdings, LLC Estrogen receptor modulators for treating mutants
JP2023514454A (ja) * 2020-02-25 2023-04-05 ユニバーシティ オブ テネシー リサーチ ファウンデーション 選択的アンドロゲン受容体分解剤（ｓａｒｄ）リガンドおよびその使用方法
CN115916170A (zh) 2020-04-17 2023-04-04 埃萨制药股份有限公司 固体形式的n-末端结构域雄激素受体抑制剂及其用途
EP4138834A1 (en) * 2020-04-24 2023-03-01 Astrazeneca AB Dosage regimen for the treatment of cancer
JP2024503718A (ja) * 2021-01-15 2024-01-26 ユニバーシティ オブ テネシー リサーチ ファウンデーション 乳がんを治療するための薬学的組成物及びその使用方法
WO2023101710A1 (en) * 2021-12-02 2023-06-08 Veru Inc. Methods of treating breast cancers with selective androgen receptor modulators and additional therapeutic agents
WO2023172891A2 (en) * 2022-03-07 2023-09-14 Baylor College Of Medicine Biomarkers for combination therapy for er+ breast cancer
WO2023244059A1 (en) * 2022-06-15 2023-12-21 Ildong Pharmaceutical Co., Ltd. Methods of treating cancer using dual androgen receptor and pde5 inhibitor compounds
WO2024138077A1 (en) * 2022-12-21 2024-06-27 Duke University Coadministration of estrogen with estrogen receptor modulator or degrader or er targeted protac for the treatment of estrogen responsive cancers

Family Cites Families (163)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3256096A (en) 1961-08-11 1966-06-14 Organic Nutrients Inc Anabolic stimulator as a poultry feed supplement
US3239345A (en) 1965-02-15 1966-03-08 Estrogenic compounds and animal growth promoters
US3949085A (en) 1970-05-27 1976-04-06 Chinoin Gyogyszer-Es Vegyeszeti Termakek Gyara Rt Anabolic-weight-gain promoting compositions containing isoflavone derivatives and method using same
US4411890A (en) 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
GB1360001A (en) 1971-06-16 1974-07-17 Scherico Ltd Pharmaceutical compositions comprising substituted anilides
US3875229A (en) 1972-11-24 1975-04-01 Schering Corp Substituted carboxanilides
US3865801A (en) 1973-06-15 1975-02-11 Atomic Energy Commission Stabilization of urinary erythropoietin using sodium p-aminosalicylate and extracting into phenol
US3946109A (en) 1973-08-08 1976-03-23 Ernst Kolb Animal feed composition containing certain vitamin combinations
US4036979A (en) 1974-01-25 1977-07-19 American Cyanamid Company Compositions containing 4,5,6,7-tetrahydrobenz[b]thien-4-yl-ureas or derivatives and methods of enhancing growth rate
US4211781A (en) 1974-09-23 1980-07-08 Pfizer Inc. Process for the preparation of dustless quinoxaline-1,4-dioxide animal feed supplement premixes
US3991750A (en) 1975-04-28 1976-11-16 Syntex Corporation Dromostanolone propionate implant pellet useful for producing weight gains in animals and suppressing estrus in female animals
JPS6044294B2 (ja) 1976-04-15 1985-10-02 帝国臓器製薬株式会社 アニリド誘導体
US4139638A (en) 1976-09-23 1979-02-13 Schering Corporation Methods for the treatment of hirsutism
DE2862100D1 (en) 1977-10-12 1983-01-05 Ici Plc Acylanilides, process for their manufacture and pharmaceutical and veterinary compositions containing them
US4191775A (en) 1977-12-15 1980-03-04 Imperial Chemical Industries Limited Amide derivatives
US4447421A (en) 1980-05-08 1984-05-08 American Cyanamid Company Process for the preparation of medicated animal feed supplement
NZ197008A (en) 1980-05-22 1984-10-19 Ici Ltd Acylanilide derivatives and pharmaceutical compositions
JPS57171904A (en) 1981-04-15 1982-10-22 Mitsubishi Petrochem Co Ltd Tri- or tetra-substituted phenoxycarboxylic acid anilide type herbicide
EP0100172B1 (en) 1982-07-23 1987-08-12 Imperial Chemical Industries Plc Amide derivatives
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
KR850004274A (ko) 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
FR2576025B1 (fr) 1985-01-14 1987-01-23 Roussel Uclaf Nouveaux steroides substitues en position 10, leur procede et les intermediaires de preparation, leur application comme medicaments, les compositions pharmaceutiques les contenant
US4670249A (en) 1985-04-12 1987-06-02 International Minerals & Chemical Corp. Growth-promoting compositions
US4837004A (en) 1985-10-18 1989-06-06 Eastman Kodak Company Rumen-stable pellets
US4904473A (en) 1986-06-23 1990-02-27 International Minerals & Chemical Corp. Ruminant feed antacid containing potassium, sodium and chlorine
GB8617653D0 (en) 1986-07-18 1986-08-28 Ici Plc Amide derivatives
GB8617652D0 (en) 1986-07-18 1986-08-28 Ici Plc Acylanilide derivatives
US4849447A (en) 1987-10-13 1989-07-18 Pitman-Moore, Inc. Zearalanol derivatives with anabolic activity
ATE122357T1 (de) 1988-01-28 1995-05-15 Polygen Holding Corp Polypeptide mit hormonwachstumsbefreiender wirkung.
ATE113607T1 (de) 1988-01-28 1994-11-15 Polygen Holding Corp Polypeptidverbindungen mit wachstumshormonfreisetzender aktivität.
US4977288A (en) 1988-01-29 1990-12-11 President And Fellows Of Harvard College M-aminophenyltrialkylstannane
US5162504A (en) 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
US5179080A (en) 1989-08-31 1993-01-12 Clinical Homecare, Corp. Formulations containing growth hormone and nutritional supplements, and methods of treating malnutrition in chronic lung disease
KR100263845B1 (ko) 1989-10-13 2000-08-16 스튜어트 엘.왓트 에리트로포이에틴 동형체와 그의 제조방법 및 그를 포함하는제약학적 조성물
US5030657A (en) 1989-10-23 1991-07-09 University Of Georgia Research Foundation, Inc. L-carnitine supplemented catfish diet
US5288496A (en) 1990-05-15 1994-02-22 Stolle Research & Development Corporation Growth promoters for animals
US5663146A (en) 1991-08-22 1997-09-02 Administrators Of The Tulane Educational Fund Polypeptide analogues having growth hormone releasing activity
CA2181358A1 (en) 1994-01-21 1995-07-27 Nancy M. Gray Methods and compositions for treating androgen-dependent diseases using optically pure r-(-)-casodex
US5609849A (en) 1994-03-11 1997-03-11 The Trustees Of The University Of Pennsylvania Serotonin (5-HT1A) receptor ligands and imaging agents
EP0683172B1 (en) 1994-05-19 1997-08-13 Akzo Nobel N.V. 11,21-Bisphenyl-19-norpregnane derivatives
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5656651A (en) 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
WO1998005962A1 (en) 1996-08-02 1998-02-12 Panvera Corporation A method for quantitating competitive binding of molecules to proteins utilizing fluorescence polarization
US20090264534A1 (en) 1996-11-27 2009-10-22 Dalton James T Selective androgen receptor modulators
US20050038110A1 (en) 2000-08-24 2005-02-17 Steiner Mitchell S. Selective androgen receptor modulators and methods of use thereof
US6071957A (en) 1996-11-27 2000-06-06 The University Of Tennessee Research Corporation Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer
US7205437B2 (en) 1996-11-27 2007-04-17 University Of Tennessee Research Foundation Selective androgen receptor modulators
US6492554B2 (en) 2000-08-24 2002-12-10 The University Of Tennessee Research Corporation Selective androgen receptor modulators and methods of use thereof
US7518013B2 (en) 2000-08-24 2009-04-14 University Of Tennessee Research Foundation Selective androgen receptor modulators
US7759520B2 (en) 1996-11-27 2010-07-20 University Of Tennessee Research Foundation Synthesis of selective androgen receptor modulators
US6995284B2 (en) 2000-08-24 2006-02-07 The University Of Tennessee Research Foundation Synthesis of selective androgen receptor modulators
AU5729098A (en) 1996-12-24 1998-07-17 Zymogenetics Inc. Treatment agents and methods for treating type ii diabetes and symptoms of type ii diabetes
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
WO1998053826A1 (en) 1997-05-30 1998-12-03 The University Of Tennessee Research Corporation Non-steroidal agonist compounds and their use in male hormone therapy
AU7723198A (en) 1997-06-04 1998-12-21 University Of Tennessee Research Corporation, The Non-steroidal radiolabeled agonist/antagonist compounds and their use in prostate cancer imaging
EP0903146A1 (en) 1997-09-23 1999-03-24 Applied Research Systems ARS Holdings N.V. 21-Hydroy-6,19-oxidoprogesterone (210h-60p) as antiglucocorticoid
US6022137A (en) 1998-04-29 2000-02-08 Buckeye Feed Mills, Inc. Conditioner for processing raw grain composition to produce pelletized feed
ID26984A (id) 1998-07-06 2001-02-22 Bristol Myers Squibb Co Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda
PT1140184E (pt) 1998-12-23 2003-10-31 Searle Llc Combinacoes de inibidores de proteina de transferencia de ester de colesterilo com derivados de acido nicotinico para indicacoes cardiovasculares
SI1169312T1 (en) 1999-03-29 2005-02-28 F. Hoffmann-La Roche Ag Glucokinase activators
US6548529B1 (en) 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
WO2001027086A1 (en) 1999-10-14 2001-04-19 Kaken Pharmaceutical Co., Ltd. Tetrahydroquinoline derivatives
WO2001027622A1 (en) 1999-10-14 2001-04-19 Bristol-Myers Squibb Company Crystallographic structure of the androgen receptor ligand binding domain
HK1048298A1 (zh) 1999-10-19 2003-03-28 Biocon Limited 比卡鲁胺(casodex)及其衍生物以及其中间产物的对映体的不对称合成法
PL360059A1 (en) 1999-10-27 2004-09-06 Nobex Corporation Resolution of intermediates in the synthesis of substantially pure bicalutamide
US6353111B1 (en) 1999-12-15 2002-03-05 Hoffmann-La Roche Inc. Trans olefinic glucokinase activators
WO2001049709A1 (en) 2000-01-03 2001-07-12 Ramot University Authority For Applied Research & Industrial Development Ltd. Glycogen synthase kinase-3 inhibitors
US6441197B1 (en) 2000-01-20 2002-08-27 Daiichi Pure Chemicals Co., Ltd. Diaminofluorescein derivative
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
US7713989B2 (en) 2000-04-27 2010-05-11 Dow Robert L Glucocorticoid receptor modulators
EP1299094A2 (en) 2000-06-28 2003-04-09 Bristol-Myers Squibb Company Selective androgen receptor modulators and methods for their identification, design and use
US8445534B2 (en) 2000-08-24 2013-05-21 University Of Tennessee Research Foundation Treating androgen decline in aging male (ADAM)-associated conditions with SARMs
US6998500B2 (en) 2000-08-24 2006-02-14 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US7622503B2 (en) 2000-08-24 2009-11-24 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US20040260108A1 (en) 2001-06-25 2004-12-23 Dalton James T. Metabolites of selective androgen receptor modulators and methods of use thereof
PT1401801E (pt) 2000-08-24 2007-02-28 Univ Tennessee Res Foundation Modulares selectivos de receptor de androgénio e métodos para a sua utilização
US7645898B2 (en) 2000-08-24 2010-01-12 University Of Tennessee Research Foundation Selective androgen receptor modulators and method of use thereof
US20020173495A1 (en) 2000-08-24 2002-11-21 Dalton James T. Selective androgen receptor modulators and methods of use thereof
US7026500B2 (en) 2000-08-24 2006-04-11 University Of Tennessee Research Foundation Halogenated selective androgen receptor modulators and methods of use thereof
US7855229B2 (en) 2000-08-24 2010-12-21 University Of Tennessee Research Foundation Treating wasting disorders with selective androgen receptor modulators
US20030232792A1 (en) 2000-08-24 2003-12-18 Dalton James T. Selective androgen receptor modulators and methods of use thereof
US20070173546A1 (en) 2000-08-24 2007-07-26 Dalton James T Selective androgen receptor modulators and method of use thereof
US8008348B2 (en) 2001-12-06 2011-08-30 University Of Tennessee Research Foundation Treating muscle wasting with selective androgen receptor modulators
US7919647B2 (en) 2000-08-24 2011-04-05 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US6838484B2 (en) 2000-08-24 2005-01-04 University Of Tennessee Research Foundation Formulations comprising selective androgen receptor modulators
US20030229099A1 (en) 2000-08-30 2003-12-11 Zhu Hugh Y. Novel farnesyl protein transferase inhibitors as antitumor agents
US6777446B2 (en) 2000-09-05 2004-08-17 Tularik, Inc. FXR modulators
AU2001286243A1 (en) 2000-09-14 2002-03-26 Kaken Pharmaceutical Co., Ltd. Tetrahydroquinoline compounds
SE0102300D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
US6645974B2 (en) 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
JP2003137814A (ja) 2001-08-10 2003-05-14 Takeda Chem Ind Ltd ＧｎＲＨアゴニストの併用剤
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
US20060004042A1 (en) 2001-08-23 2006-01-05 Dalton James T Formulations comprising selective androgen receptor modulators
CA2468719C (en) 2001-11-29 2011-05-24 Gtx Inc. Prevention and treatment of androgen-deprivation induced osteoporosis
US20070161608A1 (en) 2001-12-06 2007-07-12 Dalton James T Selective androgen receptor modulators for treating muscle wasting
WO2003049675A2 (en) 2001-12-06 2003-06-19 Gtx, Inc. Treating muscle wasting with selective androgen receptor modulators
US8853266B2 (en) 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
EP1474139B1 (en) 2002-02-01 2007-11-21 Merck & Co., Inc. 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
PT1480634E (pt) 2002-02-07 2011-10-12 Univ Tennessee Res Foundation Moduladores selectivos do receptor do androgénio (sarms) para o tratamento da hiperplasia benigna da próstata
US7803970B2 (en) 2002-02-28 2010-09-28 University Of Tennessee Research Foundation Multi-substitued selective androgen receptor modulators and methods of use thereof
US7772433B2 (en) 2002-02-28 2010-08-10 University Of Tennessee Research Foundation SARMS and method of use thereof
US7214693B2 (en) 2002-10-15 2007-05-08 University Of Tennessee Research Foundation Heterocyclic selective androgen receptor modulators and methods of use thereof
ATE533494T1 (de) 2002-02-28 2011-12-15 Univ Tennessee Res Foundation Mehrfach substituierte selektive androgen- rezeptor-modulatoren und anwendungsverfahren dafür
EP1487780A4 (en) 2002-02-28 2005-11-16 Univ Tennessee Res Foundation HALOACETAMIDE AND AZID SUBSTITUTED COMPOUNDS AND METHODS OF USE THEREOF
WO2003074450A2 (en) 2002-02-28 2003-09-12 The University Of Tennessee Research Corporation Radiolabeled selective androgen receptor modulators and their use in prostate cancer imaging and therapy
CA2477737C (en) 2002-02-28 2012-08-07 The University Of Tennessee Research Corporation Multi-substituted selective androgen receptor modulators and methods of use thereof
HRP20040822A2 (en) 2002-03-13 2005-06-30 Merck & Co. Inc. Fluorinated 4-azasteroid derivatives as androgen receptor modulators
AR040241A1 (es) 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
WO2003106401A1 (en) 2002-06-17 2003-12-24 University Of Tennessee Research Foundation N-bridged selective androgen receptor modulators and methods of use thereof
EP1398029A1 (en) 2002-09-10 2004-03-17 LION Bioscience AG NR3B1 nuclear receptor binding 3-substituted pyrazole derivatives
US20040224979A1 (en) 2002-10-15 2004-11-11 Dalton James T. Treating obesity with selective androgen receptor modulators
CA2502209A1 (en) 2002-10-15 2004-04-29 University Of Tennessee Research Foundation Methylene-bridged selective androgen receptor modulators and methods of use thereof
US20040265916A1 (en) 2002-10-15 2004-12-30 Dalton James T. Method for detecting selective androgen receptor modulators
US20040197928A1 (en) 2002-10-15 2004-10-07 Dalton James T. Method for detecting selective androgen receptor modulators
US20040087810A1 (en) 2002-10-23 2004-05-06 Dalton James T. Irreversible selective androgen receptor modulators and methods of use thereof
US8309603B2 (en) * 2004-06-07 2012-11-13 University Of Tennessee Research Foundation SARMs and method of use thereof
US20140011774A1 (en) 2002-12-05 2014-01-09 University Of Tennessee Research Foundation Selective androgen receptor modulators
JP2006517807A (ja) 2002-12-30 2006-08-03 パーデュー・リサーチ・ファウンデーション 中枢神経系の損傷の治療方法
AU2004204800B8 (en) 2003-01-13 2011-05-26 University Of Tennessee Research Foundation Large-scale synthesis of selective androgen receptor modulators
WO2004066922A2 (en) * 2003-01-22 2004-08-12 Gtx Inc. A method of treating breast cancer with androgen receptor antagonists
WO2004064747A2 (en) * 2003-01-22 2004-08-05 Gtx Inc. Treating androgen deficiency in female (adif)-associated conditions with sarms
US20040167103A1 (en) * 2003-02-24 2004-08-26 Dalton James T. Haloacetamide and azide substituted compounds and methods of use thereof
GB0308335D0 (en) 2003-04-10 2003-05-14 Novartis Ag Organic compounds
CN1325506C (zh) 2003-05-15 2007-07-11 中国科学院上海药物研究所 骨重吸收抑制剂阿伦膦酸及生理可接受的盐和它的制备
EP1643971A2 (en) 2003-05-22 2006-04-12 Neopharm, Inc. Liposomal formulations comprising a combination of two or more active agents
FI20030958A0 (fi) 2003-06-27 2003-06-27 Orion Corp Uusia yhdisteitä
WO2005025579A1 (en) 2003-09-10 2005-03-24 Merck & Co., Inc. 17-heterocyclic-4-azasteroid derivatives as androgen receptor modulators
SI1696909T1 (sl) 2003-09-12 2008-02-29 Serono Lab Derivati benzotiazola za zdravljenje diabetesa
EA013738B1 (ru) 2003-10-14 2010-06-30 Юниверсити Оф Теннесси Рисерч Фаундейшн Лечение нарушений костной ткани с использованием селективных модуляторов адрогенных рецепторов
TW200523235A (en) 2003-10-15 2005-07-16 Gtx Inc Anti-cancer compounds and methods of use thereof
US20050137172A1 (en) * 2003-10-15 2005-06-23 Dalton James T. Haloacetamide and azide substituted compounds and methods of use thereof
GB0325402D0 (en) 2003-10-31 2003-12-03 Astrazeneca Ab Compounds
KR20060115325A (ko) 2003-12-16 2006-11-08 지티엑스, 인코포레이티드 선택적 안드로겐 수용체 모듈레이터의 프로드럭 및 그의이용 방법
TW200530181A (en) 2004-01-13 2005-09-16 Bristol Myers Squibb Co Heterocyclic compounds useful as growth hormone secretagogues
RU2368612C2 (ru) 2004-05-03 2009-09-27 Ф.Хоффманн-Ля Рош Аг Индолилпроизводные в качестве модуляторов печеночного х-рецептора
US20110237664A1 (en) * 2004-06-07 2011-09-29 Dalton James T Selective androgen receptor modulators for treating diabetes
PL2289872T3 (pl) 2004-06-07 2017-12-29 University Of Tennessee Research Foundation Medyczne zastosowania selektywnego modulatora receptora androgenowego
US20130034562A1 (en) 2004-06-07 2013-02-07 Dalton James T Selective androgen receptor modulators for treating diabetes
EP1781271A1 (en) 2004-07-14 2007-05-09 Janssen Pharmaceutica N.V. Arylidenes for the treatment of estrogen related receptor-alpha mediated diseases
US7825229B2 (en) 2005-03-25 2010-11-02 Rosetta Genomics Ltd. Lung cancer-related nucleic acids
CN101299920A (zh) 2005-08-31 2008-11-05 田纳西大学研究基金会 用选择性雄激素受体调节剂治疗肾病、烧伤、创伤和脊髓损伤
CN101316836A (zh) 2005-11-01 2008-12-03 詹森药业有限公司 作为葡萄糖激酶变构调节剂的取代的二氢异吲哚酮类
WO2007053662A1 (en) 2005-11-01 2007-05-10 Janssen Pharmaceutica N.V. Dihydroisoindolones as allosteric modulators of glucokinase
AU2006318400C1 (en) 2005-11-28 2013-01-17 Gtx, Inc. Nuclear receptor binding agents
US8158828B2 (en) 2005-11-28 2012-04-17 Gtx, Inc. Nuclear receptor binding agents
WO2007075702A2 (en) 2005-12-21 2007-07-05 Schering Corporation Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and h3 receptor antagonist/inverse agonist
EP1801140A1 (en) 2005-12-22 2007-06-27 Mnemoscience GmbH Macro-diacrylate
RU2448697C2 (ru) * 2006-03-22 2012-04-27 Медигене Аг Лечение рака молочной железы, негативного по трем рецепторам
AU2007272950B2 (en) 2006-07-12 2012-11-01 University Of Tennessee Research Foundation Substituted acylanilides and methods of use thereof
PL2054049T3 (pl) 2006-08-24 2016-11-30 Podstawione acyloanilidy i sposoby ich stosowania
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
BRPI0806371A2 (pt) 2007-01-22 2011-09-13 Gtx Inc agentes ligação de receptor nuclear
KR20170001736A (ko) 2007-09-11 2017-01-04 지티엑스, 인코포레이티드 고형의 선택적인 안드로겐 수용체 모듈레이터
US7968603B2 (en) 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
US8003689B2 (en) 2008-06-20 2011-08-23 Gtx, Inc. Metabolites of selective androgen receptor modulators and methods of use thereof
EP2486149B1 (en) * 2009-08-06 2015-06-17 John Wayne Cancer Institute Diagnosis of primary and metastatic basal-like breast cancer and other cancer types
CN102573472A (zh) * 2009-10-23 2012-07-11 健康研究公司 治疗雄激素受体阳性癌症的方法
KR20120115380A (ko) 2010-01-11 2012-10-17 지티엑스, 인코포레이티드 마이봄선 기능 장애의 치료 방법
UY33740A (es) * 2010-11-18 2012-05-31 Takeda Pharmaceutical Método para tratar el cáncer de mama y cáncer de ovarios
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
MX375256B (es) 2012-07-13 2025-03-06 Gtx Inc Metodo para tratar canceres de mama positivos a receptor de androgeno (ar) con modulador de receptor de androgeno selectivo (sarms).
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)

Also Published As

Publication number Publication date
US9604916B2 (en) 2017-03-28
CN110840870A (zh) 2020-02-28
HUE052574T2 (hu) 2021-05-28
JP2017101088A (ja) 2017-06-08
JP2018168201A (ja) 2018-11-01
EP2872482A4 (en) 2016-03-30
AU2018201450B2 (en) 2019-06-13
RU2015104780A (ru) 2016-08-27
CY1123542T1 (el) 2022-03-24
KR20150038085A (ko) 2015-04-08
KR102238970B1 (ko) 2021-04-09
AU2013203600C1 (en) 2016-11-24
ES2818915T3 (es) 2021-04-14
EP2872482A2 (en) 2015-05-20
IL236681B (en) 2021-04-29
EP3733170A1 (en) 2020-11-04
PL2872482T3 (pl) 2021-03-08
AU2013203600B2 (en) 2016-03-03
DK2872482T3 (da) 2020-09-21
KR102122941B1 (ko) 2020-06-15
AU2018201450A1 (en) 2018-03-22
AU2016203696A1 (en) 2016-06-23
IL236681A0 (en) 2015-02-26
CN108143728A (zh) 2018-06-12
JP2015522069A (ja) 2015-08-03
KR20200069394A (ko) 2020-06-16
RU2648959C2 (ru) 2018-03-28
JP6386120B2 (ja) 2018-09-05
PT2872482T (pt) 2020-09-22
RU2017141776A3 (es) 2019-02-13
RU2717835C2 (ru) 2020-03-26
WO2014011220A3 (en) 2015-03-05
AU2016203696B2 (en) 2017-11-30
IN2015DN01046A (es) 2015-06-26
CA2879049A1 (en) 2014-01-16
CN104754939A (zh) 2015-07-01
HRP20201463T1 (hr) 2021-04-02
MX2015000572A (es) 2015-09-23
AU2013203600A1 (en) 2014-01-30
MX2020009725A (es) 2020-10-08
JP6759290B2 (ja) 2020-09-23
WO2014011220A2 (en) 2014-01-16
RU2017141776A (ru) 2019-02-13
CA2879049C (en) 2021-02-23
LT2872482T (lt) 2020-12-28
JP6226978B2 (ja) 2017-11-08
US20140018433A1 (en) 2014-01-16
EP2872482B1 (en) 2020-07-08

Similar Documents

Publication Publication Date Title
MX375256B (es) Metodo para tratar canceres de mama positivos a receptor de androgeno (ar) con modulador de receptor de androgeno selectivo (sarms).
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
MX2017004526A (es) Terapia combinada de anticuerpos biespecificos especificos para fap y dr5 y agentes quimioterapeuticos.
MX2019008207A (es) Métodos para tratar el cáncer con anticuerpos anti-pd-1.
MX2016002826A (es) Anticuerpos anti-b7-h1 para tratar tumores.
MX2022001757A (es) Inhibidores de muerte programada 1 (pd-19)/ligando de muerte programada 1 (pd-l1) para el tratamiento de cancer.
PH12017500639A1 (en) Neuroactive compounds and methods of use thereof
PH12019500261B1 (en) Methods for treating osteogenesis imperfecta
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
MX2020011772A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
PH12016501672A1 (en) Anti-cd38 antibodies for treatment of acute lymphoblastic leukemia
EP3552665A3 (en) Antibodies
MX2021002406A (es) Composiciones farmaceuticas que comprenden un inhibidor de il-4r para usarse en el tratamiento de la esofagitis eosinofilica.
PH12021552742A1 (en) Afucosylated anti-fgfr2iiib antibodies
IL240060A0 (en) Treatment involving antibodies against claudin 2. 18 for the treatment of cancer
GEP201706612B (en) Methods for the treatment of breast cancer
MX368508B (es) Benralizumab para usarse en la reducción de la tasa de exacerbación de asma.
MX2014004074A (es) Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2.
AR086390A1 (es) Metodo para el tratamiento de malignidades solidas que incluyen malignidades solidas avanzadas o metastasicas
SMT202200458T1 (it) Terapia combinata con anticorpi contro la claudina 18.2 per il trattamento del cancro
PH12016502244A1 (en) Hsp70 modulators and methods for making and using the same
PL2976360T3 (pl) Terapia obejmująca przeciwciała przeciwko klaudynie 18.2 do leczenia nowotworu złośliwego
NZ724799A (en) Compositions and methods for the treatment or prevention of neurodegenerative disorders
UA85798U (ru) Способ лечения йодозависимых заболеваний щитовидной железы

Legal Events

Date Code Title Description
FG Grant or registration